Rockefeller Capital Management L.P. Reduces Stock Position in The Clorox Company (NYSE:CLX)

Rockefeller Capital Management L.P. cut its stake in The Clorox Company (NYSE:CLX) by 4.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,156 shares of the company’s stock after selling 751 shares during the period. Rockefeller Capital Management L.P.’s holdings in Clorox were worth $2,469,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Mizuho Securities USA LLC increased its holdings in Clorox by 46,877.8% in the third quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company’s stock valued at $733,095,000 after buying an additional 4,490,421 shares in the last quarter. Nuance Investments LLC increased its holdings in Clorox by 150.6% in the second quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock valued at $218,035,000 after buying an additional 960,094 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Clorox by 2.2% during the 3rd quarter. Van ECK Associates Corp now owns 1,492,717 shares of the company’s stock worth $237,372,000 after purchasing an additional 31,510 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Clorox by 14.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 961,387 shares of the company’s stock worth $131,200,000 after purchasing an additional 120,716 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Clorox by 11.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 802,237 shares of the company’s stock worth $109,483,000 after purchasing an additional 85,529 shares in the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Stock Down 1.6 %

Shares of CLX opened at $166.97 on Friday. The firm has a market cap of $20.67 billion, a PE ratio of 58.18, a price-to-earnings-growth ratio of 3.09 and a beta of 0.42. The company’s fifty day moving average is $163.42 and its two-hundred day moving average is $150.16. The Clorox Company has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The company has a quick ratio of 0.62, a current ratio of 1.00 and a debt-to-equity ratio of 11.08.

Clorox (NYSE:CLX) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.50. The company had revenue of $1.76 billion for the quarter, compared to analyst estimates of $1.64 billion. Clorox had a net margin of 4.78% and a return on equity of 316.08%. Clorox’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter last year, the business earned $0.49 EPS. Analysts forecast that The Clorox Company will post 6.85 earnings per share for the current year.

Clorox Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 29th will be issued a dividend of $1.22 per share. The ex-dividend date is Wednesday, January 29th. This represents a $4.88 annualized dividend and a dividend yield of 2.92%. Clorox’s payout ratio is 170.04%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CLX shares. Citigroup raised their price objective on shares of Clorox from $165.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, September 6th. Jefferies Financial Group raised shares of Clorox from a “hold” rating to a “buy” rating and raised their price objective for the stock from $174.00 to $187.00 in a research note on Tuesday, October 1st. Barclays raised their price objective on shares of Clorox from $137.00 to $139.00 and gave the stock an “underweight” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. raised their price objective on shares of Clorox from $148.00 to $174.00 and gave the stock a “neutral” rating in a research note on Friday, October 11th. Finally, BNP Paribas raised shares of Clorox to a “strong sell” rating in a research note on Friday, September 6th. Five equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $155.00.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.